HPV状态与肿瘤部位亚组分析:西妥昔单抗对比顺铂联合同期放疗
该研究为CTXMAB+RT随机II期试验的亚组分析,按p16阳性口咽癌、p16阴性口咽癌及其他部位分组,比较同期西妥昔单抗或顺铂联合放疗的疗效。p16阳性口咽癌组样本量小未达统计学显著,但2年局部控制率和总生存/病因特异性生存率数值上均倾向顺铂组(100% vs 72.9%和100% vs 77.8%),且严重或致死性感染并发症仅见于西妥昔单抗组。
要点
- p16阳性口咽癌患者中,西妥昔单抗组疗效可能低于顺铂组,但样本量小未达统计学显著。
- p16阳性口咽癌组2年局部控制率:顺铂100% vs 西妥昔单抗72.9%;2年OS/CSS率:顺铂100% vs 西妥昔单抗77.8%。
- 严重或致死性感染并发症仅发生于西妥昔单抗组。
核心结论
- 在CTXMAB+RT试验的p16阳性口咽癌患者中,西妥昔单抗的疗效低于顺铂,可能对该临床情境下的治疗选择有提示意义。
研究设计与样本
- CTXMAB+RT随机II期试验的亚组分析,将患者分为p16阳性口咽癌、p16阴性口咽癌和其他部位三组。
- 共33例口咽癌患者,其中30例有HPV状态;3例接受顺铂但HPV状态未知者被排除出生存分析。
主要发现
- 各组患者数少,任何分析指标均未达到统计学显著性。
- p16阳性组中,2年局部控制率和总生存/病因特异性生存率数值上倾向顺铂组(100% vs 72.9%和100% vs 77.8%,顺铂 vs 西妥昔单抗)。
- p16阳性组中,治疗臂(西妥昔单抗 vs 顺铂)的风险比:局部控制为4.7(95%CI 0.5-40.3),总生存为3.4(95%CI 0.4-30.5),病因特异性生存为2.4(95%CI 0.2-23.2)。
- p16阴性口咽癌组或其他部位患者中,未观察到倾向顺铂组的生存获益。
- 严重或致死性感染并发症仅发生于西妥昔单抗组。
临床怎么用
- 对于p16阳性口咽癌患者,选择同期放疗方案时需权衡西妥昔单抗疗效可能低于顺铂及感染并发症风险。
局限性
- 亚组样本量小,未达到统计学显著性,结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We report a subgroup analysis primarily focused on human papillomavirus (HPV)-related oropharyngeal cancer (OPC) from the Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer (CTXMAB+RT; ClinicalTrials.gov identifier NCT01216020) trial comparing radiation therapy with concomitant cisplatin (CDDP) versus concomitant cetuximab (CTX) as first-line treatment of locally advanced head and neck cancer. METHODS AND MATERIALS: The data from all the patients in the CTXMAB+RT trial were reviewed and separately analyzed in 3 groups: p16-positive OPC, p16-negative OPC, and all other cancer sites. The endpoints of interest were locoregional control (LC), metastasis-free survival, cancer-specific survival (CSS), and overall survival (OS). Severe and fatal infectious complications were also reanalyzed to more thoroughly investigate the association between CTX treatment and potentially life-threatening reactions. RESULTS: A total of 33 patients had OPC. The HPV status was available for 30 of the 33 patients. Thus, 3 patients treated with CDDP but with unknown HPV status were excluded from the survival analysis. The small number of patients in each group did not allow for significance to be reached for any of the outcomes analyzed. A trend favored the CDDP arm in the p16-positive group for the 2-year LC and OS/CSS rates (100% vs 72.9% and 100% vs 77.8% for CDDP vs CTX). In this group of patients, the hazard ratio for the treatment arm (CTX vs CDDP) was 4.7 (95% confidence interval [CI] 0.5-40.3) for LC, 3.4 (95% CI 0.4-30.5) for OS, and 2.4 for CSS (95% CI 0.2-23.2). A survival benefit favoring the CDDP arm was not evident in the p16-negative OPC group or for patients with cancer located in other sites. Serious or fatal infectious complications occurred only in the CTX arm. CONCLUSIONS: In patients with p16-positive OPC in the CTXMAB+RT trial, CTX had lower efficacy than CDDP, with possible implications for treatment selection in this clinical setting.
引用
- Buglione M, Maddalo M, Corvò R, et al. Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2016. PMID: 27986347. doi:10.1016/j.ijrobp.2016.10.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。